Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of bedaquiline fumarate丨cas 845533-86-0 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.
Specifications of Bedaquiline Fumarate丨CAS 845533-86-0
|
Appearance |
White to off-white solid |
|
Identification |
The retention time of the major peak in the chromatogram of Assay preparation corresponds to that of the standard preparation as obtained in the assay |
|
Purity |
99.5% min |
|
Single impurity |
0.1% max |
|
Total impurity |
0.5% max |
|
Loss on drying |
1.0% max |
|
Residue on ignition |
1.0% max |
Applications
Treatment of Multidrug-Resistant Tuberculosis (MDR-TB)
Bedaquiline Fumarate丨CAS 845533-86-0 is specifically developed for the treatment of pulmonary MDR-TB in adults and adolescents.
It is used in combination with other anti-TB drugs as part of a comprehensive regimen.
Approved by regulatory bodies such as the U.S. FDA, WHO, and EMA for limited use under specific clinical conditions.
Compassionate Use in Drug-Resistant Infections
Sometimes utilized in extensively drug-resistant tuberculosis (XDR-TB) under emergency or compassionate programs.
Being explored in clinical trials for other mycobacterial infections such as non-tuberculous mycobacteria (NTM).
Benefits
Novel Mechanism of Action
Bedaquiline targets mycobacterial ATP synthase, a unique mechanism that inhibits energy production in Mycobacterium tuberculosis, including resistant strains.
Effective Against Resistant Strains
One of the few available drugs with strong efficacy against MDR- and XDR-TB, offering hope for otherwise untreatable cases.
Improved Treatment Outcomes
Clinical studies have shown faster sputum culture conversion, reduced disease transmission, and improved long-term survival when used appropriately.
Oral Administration
Convenient oral dosing (usually 400 mg/day initially) enhances patient compliance compared to injectable regimens.
Global Health Impact
Endorsed by global health initiatives as a breakthrough drug in the fight against drug-resistant TB, especially in high-burden countries.
Conclusion
Bedaquiline Fumarate丨CAS 845533-86-0 represents a significant advancement in the treatment of multidrug-resistant tuberculosis. With its novel action and proven clinical effectiveness, it plays a critical role in modern TB management protocols. Continued access and careful stewardship are essential to preserving its efficacy for future generations.

